ESMO 2022 Conference Coverage


 

Lecture Summary - ESMO 2022 on PROs From the Randomized Phase 3 Study DESTINY-Breast04: T-DXd vs. Treatment of Physician’s Choice in HER2-Low mBC

28 views
October 3, 2022
Comments 0
Login to view comments. Click here to Login